MITRA Fundamental Analysis - Mithra Pharmaceuticals SA

Fundamental Rating

MITRA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. MITRA has a bad profitability rating. Also its financial health evaluation is rather negative. MITRA is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MITRA has reported negative net income.

In the past year MITRA has reported a negative cash flow from operations.

MITRA had negative earnings in each of the past 5 years.

MITRA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -21.04%, MITRA is doing worse than 71.74% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-21.04%
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 66.54%, MITRA is in line with its industry, outperforming 45.65% of the companies in the same industry.

MITRA's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for MITRA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	66.54%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-9.77%

GM growth 5Y-14.16%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MITRA does not have a ROIC to compare to the WACC, probably because it is not profitable.

There is no outstanding debt for MITRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

MITRA has an Altman-Z score of -1.88. This is a bad value and indicates that MITRA is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -1.88, MITRA is doing worse than 71.74% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-1.88

ROIC/WACCN/A

WACC3.99%

2.3 Liquidity

MITRA has a Current Ratio of 1.04. This is a normal value and indicates that MITRA is financially healthy and should not expect problems in meeting its short term obligations.

MITRA's Current ratio of 1.04 is on the low side compared to the rest of the industry. MITRA is outperformed by 80.43% of its industry peers.

MITRA has a Quick Ratio of 1.04. This is a bad value and indicates that MITRA is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Quick ratio value of 0.49, MITRA is not doing good in the industry: 89.13% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.04
Quick Ratio	0.49

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.70% over the past year.

MITRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 186.41%.

Measured over the past years, MITRA shows a decrease in Revenue. The Revenue has been decreasing by -7.05% on average per year.

EPS 1Y (TTM)32.7%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-27.42%

Revenue 1Y (TTM)186.41%

Revenue growth 3Y64.44%

Revenue growth 5Y-7.05%

Sales Q2Q%-38.06%

3.2 Future

MITRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.23% yearly.

Based on estimates for the next years, MITRA will show a very strong growth in Revenue. The Revenue will grow by 80.47% on average per year.

EPS Next Y32.9%

EPS Next 2Y49.56%

EPS Next 3Y40.23%

EPS Next 5YN/A

Revenue Next Year175.31%

Revenue Next 2Y104.65%

Revenue Next 3Y80.47%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MITRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MITRA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as MITRA's earnings are expected to grow with 40.23% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y49.56%

EPS Next 3Y40.23%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MITRA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

Mithra Pharmaceuticals SA

EBR:MITRA (4/26/2024, 7:00:00 PM)

0.216

0 (-1.82%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)03-08 2024-03-08/amc

Earnings (Next)09-26 2024-09-26

Inst OwnersN/A

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap14.93M

Revenue(TTM)62.67M

Net Income(TTM)-78.84M

Analysts35.56

Price Target3.8 (1659.26%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-0.13%

PT rev (3m)-8.7%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-5.59%

EPS NY rev (3m)-122.19%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.24
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-1.42

EYN/A

EPS(NY)-0.58

Fwd EYN/A

FCF(TTM)-0.41

FCFYN/A

OCF(TTM)-0.14

OCFYN/A

SpS0.91

BVpS-0.13

TBVpS-2.18

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-21.04%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	66.54%
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-9.77%

GM growth 5Y-14.16%

F-Score4

Asset Turnover0.17

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	154.6%
Cap/Sales	30.26%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.04
Quick Ratio	0.49
Altman-Z	-1.88

F-Score4

WACC3.99%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)32.7%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-27.42%

EPS Next Y32.9%

EPS Next 2Y49.56%

EPS Next 3Y40.23%

EPS Next 5YN/A

Revenue 1Y (TTM)186.41%

Revenue growth 3Y64.44%

Revenue growth 5Y-7.05%

Sales Q2Q%-38.06%

Revenue Next Year175.31%

Revenue Next 2Y104.65%

Revenue Next 3Y80.47%

Revenue Next 5YN/A

EBIT growth 1Y50.65%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year79.67%

EBIT Next 3Y44.47%

EBIT Next 5YN/A

FCF growth 1Y71.4%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y87.66%

OCF growth 3YN/A

OCF growth 5YN/A

Mithra Pharmaceuticals SA / MITRA.BR FAQ

What is the fundamental rating for MITRA stock?

ChartMill assigns a fundamental rating of 2 / 10 to MITRA.BR.

What is the valuation status of Mithra Pharmaceuticals SA (MITRA.BR) stock?

ChartMill assigns a valuation rating of 1 / 10 to Mithra Pharmaceuticals SA (MITRA.BR). This can be considered as Overvalued.

What is the profitability of MITRA stock?

Mithra Pharmaceuticals SA (MITRA.BR) has a profitability rating of 0 / 10.

What is the expected EPS growth for Mithra Pharmaceuticals SA (MITRA.BR) stock?

The Earnings per Share (EPS) of Mithra Pharmaceuticals SA (MITRA.BR) is expected to grow by 32.9% in the next year.

How sustainable is the dividend of Mithra Pharmaceuticals SA (MITRA.BR) stock?

The dividend rating of Mithra Pharmaceuticals SA (MITRA.BR) is 0 / 10 and the dividend payout ratio is 0%.

Mithra Pharmaceuticals SA (MITRA.BR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

Mithra Pharmaceuticals SA / MITRA.BR FAQ

What is the fundamental rating for MITRA stock?

What is the valuation status of Mithra Pharmaceuticals SA (MITRA.BR) stock?

What is the profitability of MITRA stock?

What is the expected EPS growth for Mithra Pharmaceuticals SA (MITRA.BR) stock?

How sustainable is the dividend of Mithra Pharmaceuticals SA (MITRA.BR) stock?